Angioblast raises new funds and may seek IPO
This article was originally published in Scrip
Executive Summary
Angioblast Systems has raised A$7-10 million ($5.8-8.3 million) in new funding, which it will use to take its lead development projects to Phase III trials, but may seek an initial public offering in the longer term.